First clinical experience with the new Surpass Evolve flow diverter: technical and clinical considerations. (12th February 2020)

• Record Type: Journal Article
• Authors: Orru, Emanuele; Rice, Henry; De Villiers, Laetitia; Klostranec, Jesse M; Wakhloo, Ajay K; Coon, Alexander L; Radovanovic, Ivan; Kortman, Hans; Bhatia, Kartik Dev; Krings, Timo; Pereira, Vitor M
• Is Part Of: Journal of neurointerventional surgery. Volume 12:Number 10(2020)
• Page Start: 974
• Page End: 980
• Publication Date: 2020-02-12
• Subjects: aneurysm -- flow diverter -- stent; Nervous system -- Surgery -- Periodicals; Cerebrovascular disease -- Surgery -- Periodicals; 617.48
• DOI: 10.1136/neurintsurg-2019-015734
• Languages: English
• ISSNs: 1759-8478

Abstract

Abstract : Objective: To describe the results in patients treated with the Surpass Evolve (SE) device, the new generation of Surpass flow diverters. Methods: Twenty-five consecutive patients (20 women, average age 58 years), with anterior or posterior circulation aneurysms treated with SEs in two early-user centers, were included. Device properties and related technical properties, imaging and clinical follow-up data, and intraprocedural, early (<30 days) and delayed (>30 days) neurological complications, further divided into minor (silent/non-permanent) and major (permanent) complications, were recorded and analyzed. Results: Twenty-nine SEs were successfully implanted in all subjects to treat 26 aneurysms using an 0.027" microcatheter with an average of 1.2 stents per patient. No intraprocedural thromboembolic or hemorrhagic complications were seen. At clinical follow-up, 24/25 (96%) patients had a modified Rankin Score of 0–2. Mortality was 0%. Imaging follow-up, available in 22/25 (88%) patients (median follow-up time 4 months), showed a complete aneurysm occlusion in 13/23 (57%) imaged lesions. Minor, transitory neurological deficits were recorded in 5/25 (20%) patients. One (4%) major complication was seen in one patient (4%) with a left-sided hemispheric stroke on postprocedural day 4 due to an acute stent thrombosis. Conclusions: Preliminary experience in patients demonstrates a good performance of the SE. This newly designed implant maintains the engineering characteristics of Surpass flow diverters, including precise placement due to its lower foreshortening and a high mesh density, yet can be deployed through a significantly lower-profile delivery system.